pubmed-article:18521230 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:18521230 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
pubmed-article:18521230 | lifeskim:mentions | umls-concept:C0278664 | lld:lifeskim |
pubmed-article:18521230 | lifeskim:mentions | umls-concept:C0246415 | lld:lifeskim |
pubmed-article:18521230 | lifeskim:mentions | umls-concept:C0034897 | lld:lifeskim |
pubmed-article:18521230 | lifeskim:mentions | umls-concept:C0279770 | lld:lifeskim |
pubmed-article:18521230 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
pubmed-article:18521230 | pubmed:issue | 1 | lld:pubmed |
pubmed-article:18521230 | pubmed:dateCreated | 2008-6-3 | lld:pubmed |
pubmed-article:18521230 | pubmed:abstractText | Purpose: To determine the efficacy and toxicity of docetaxel as first-line chemotherapy in adult patients with locally advanced and/or metastatic soft tissue sarcoma (STS).Patients/methods. Thirty eligible patients, with histologically proven STS, Eastern Cooperative Oncology Group (ECOG) performance status 0-2 and bidimensionally measurable disease, entered this study. None had received previous chemotherapy. Docetaxel 100 mg m(-2) was given as a 1-h intravenous infusion every 3 weeks. Patients were evaluable for response, evaluated by WHO criteria, after one cycle of chemotherapy and toxicity was graded by NCIC-CTG common toxicity criteria.Results. One hundred and thirty two cycles were aldministered, with a range per patient of 1-9. The median delivered dose intensity was 32.2 mg m(-2) weekm(-1) (planned 33.3 mg m(-2) weekm(-1) ) and 67% of patients received >/=90% planned dose intensity. There were three partial responses (10.7%; 95% confidence interval 2.3-28.2) with a median duration of 7 months (range 6.4-8.3 months). Thirty patients were evaluable for non-haematological toxicity and 28 for haematological toxicity (repeat counts were not available in two patients). Haematological toxicity was moderately severe, with 18 (64%) patients experiencing at least one episode of grade 4 neutropenia, and 7 (25%) patients experiencing febrile neutropenia.Conclusions. In this study, activity of docetaxel in adult chemotherapy-naïve patients with advanced STS was modest. | lld:pubmed |
pubmed-article:18521230 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18521230 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18521230 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18521230 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18521230 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18521230 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18521230 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18521230 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18521230 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18521230 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18521230 | pubmed:language | eng | lld:pubmed |
pubmed-article:18521230 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:18521230 | pubmed:status | PubMed-not-MEDLINE | lld:pubmed |
pubmed-article:18521230 | pubmed:issn | 1357-714X | lld:pubmed |
pubmed-article:18521230 | pubmed:author | pubmed-author:BeardRR | lld:pubmed |
pubmed-article:18521230 | pubmed:author | pubmed-author:VermaSS | lld:pubmed |
pubmed-article:18521230 | pubmed:author | pubmed-author:BramwellVV | lld:pubmed |
pubmed-article:18521230 | pubmed:author | pubmed-author:BelangerKK | lld:pubmed |
pubmed-article:18521230 | pubmed:author | pubmed-author:EisenhauerEE | lld:pubmed |
pubmed-article:18521230 | pubmed:author | pubmed-author:BlacksteinMM | lld:pubmed |
pubmed-article:18521230 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:18521230 | pubmed:volume | 2 | lld:pubmed |
pubmed-article:18521230 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:18521230 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:18521230 | pubmed:pagination | 29-33 | lld:pubmed |
pubmed-article:18521230 | pubmed:year | 1998 | lld:pubmed |
pubmed-article:18521230 | pubmed:articleTitle | A Phase II Study of Docetaxel in Chemotherapy-Naïve Patients With Recurrent or Metastatic Adult Soft Tissue Sarcoma. | lld:pubmed |
pubmed-article:18521230 | pubmed:affiliation | London Regional Cancer Centre Ontario Canada. | lld:pubmed |
pubmed-article:18521230 | pubmed:publicationType | Journal Article | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18521230 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18521230 | lld:pubmed |